Global incidence and prevalence of nonalcoholic fatty liver disease

Clinical and Molecular Hepatology, Год журнала: 2022, Номер 29(Suppl), С. S32 - S42

Опубликована: Дек. 15, 2022

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of worldwide. The estimated global incidence NAFLD 47 cases per 1,000 population and higher among males than females. prevalence adults 32% (40%) compared to females (26%). has increased over time, from 26% in studies 2005 or earlier 38% 2016 beyond. varies substantially by world region, contributed differing rates obesity, genetic socioeconomic factors. exceeds 40% the Americas South-East Asia. projected increase significantly multiple regions 2030 if current trends are left unchecked. In this review, we discuss future projections.

Язык: Английский

---

Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world

Alimentary Pharmacology & Therapeutics, Год журнала: 2022, Номер 56(6), С. 942 - 956

Опубликована: Июль 26, 2022

Summary Background The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing in parallel with obesity and type 2 diabetes. Aim To review the global epidemiology NAFLD Methods We retrieved articles from PubMed using search terms NAFLD, epidemiology, prevalence, incidence, comorbidities. Results Over 250 were reviewed. In 2016, was 25%; this increased to >30% 2019. Prevalence Asia, Latin America Middle East‐North Africa (MENA) 30.8%, 34.5% 42.6%, respectively. age. Although higher men, post‐menopausal women similar. certain subpopulations, especially among obese those metabolic syndrome (MS). However, lean 11.2%. steatohepatitis (NASH) estimated between 2% 6% general population. Approximately 7% patients have advanced fibrosis; rates 21% 50% NASH. Overall mortality related 15–20 per 1000 person‐years, substantially NASH, components MS. Recent data suggest mortality/morbidity globally but awareness remains low healthcare providers. Conclusions poses a public health problem very high burden MENA America. Research needed better quantify full impact develop strategies improve risk stratification.

Язык: Английский

---

Effects of time-restricted feeding (16/8) combined with a low-sugar diet on the management of non-alcoholic fatty liver disease: A randomized controlled trial

Nutrition, Год журнала: 2022, Номер 105, С. 111847 - 111847

Опубликована: Сен. 13, 2022

Язык: Английский

---

Management of metabolic-associated fatty liver disease: The diabetology perspective

World Journal of Gastroenterology, Год журнала: 2023, Номер 29(1), С. 126 - 143

Опубликована: Янв. 3, 2023

The metabolic syndrome as a consequence of the obesity pandemic resulted in substantial increase prevalence metabolic-associated fatty live disease (MAFLD) and type 2 diabetes mellitus (T2DM). Because similarity pathobiology shared between T2DM MAFLD, both disorders coexist many patients may potentiate disease-related outcomes with rapid progression increased complications individual diseases. In fact, awareness about this coexistence risk are often overlooked by hepatologists diabetologists. Management these patient should be addressed wholistically using an appropriate multidisciplinary team approach involving specialists and, when necessary, liaising dieticians surgeons. This comprehensive review is to compile current evidence from diabetologist's perspective on MAFLD suggest optimal management strategies.

Язык: Английский

---

Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review

Cancers, Год журнала: 2024, Номер 16(6), С. 1214 - 1214

Опубликована: Март 20, 2024

The prevalence of metabolic-associated fatty liver disease (MAFLD) is increasing globally due to factors such as urbanization, obesity, poor nutrition, sedentary lifestyles, healthcare accessibility, diagnostic advancements, and genetic influences. Research on MAFLD HCC risk factors, pathogenesis, biomarkers has been conducted through a narrative review relevant studies, with focus PubMed Web Science databases exclusion criteria based article availability language. Steatosis marks the early stage MASH advancement, commonly associated metabolic syndrome obesity type 2 diabetes. Various mechanisms, including heightened lipolysis, hepatic lipogenesis, consumption high-calorie diets, contribute accumulation lipids in liver. Insulin resistance pivotal development steatosis, it leads release free acids from adipose tissue. Natural compounds hold promise regulating lipid metabolism inflammation combat these conditions. Liver fibrosis serves significant predictor progression development, underscoring need target treatment approaches. Risk for MASH-associated encompass advanced fibrosis, older age, male gender, syndrome, predispositions, dietary habits, emphasizing requirement efficient surveillance measures. Considering important further studies determine biochemical impact order establish targeted therapies that can prevent or reduce MASH, indirectly decreasing HCC.

Язык: Английский

---

Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(4), С. 1589 - 1589

Опубликована: Фев. 13, 2025

Non-alcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction-associated steatotic (MASLD), is the most prevalent disorder globally, linked obesity, type 2 diabetes, and cardiovascular risk. Understanding its potential progression from simple steatosis cirrhosis hepatocellular carcinoma (HCC) crucial for patient management treatment strategies. The disease's complexity requires innovative approaches early detection personalized care. Omics technologies-such genomics, transcriptomics, proteomics, metabolomics, exposomics-are revolutionizing study of MASLD. These high-throughput techniques allow a deeper exploration molecular mechanisms driving progression. Genomics can identify genetic predispositions, whilst transcriptomics proteomics reveal changes in gene expression protein profiles during evolution. Metabolomics offers insights into alterations associated with MASLD, while exposomics links environmental exposures MASLD pathology. By integrating data various omics platforms, researchers map out intricate biochemical pathways involved This review discusses roles technologies enhancing understanding highlights diagnostic therapeutic targets within spectrum, emphasizing need non-invasive tools staging development.

Язык: Английский

---

Changing epidemiology of hepatocellular carcinoma in South America: A report from the South American liver research network

Annals of Hepatology, Год журнала: 2022, Номер 28(2), С. 100876 - 100876

Опубликована: Ноя. 16, 2022

Most epidemiological data on hepatocellular carcinoma (HCC) originate from resource-rich countries. We have previously described the epidemiology of HCC in South America through American Liver Research Network. Here, we provide an update changing continent seven years since that report.We evaluated all cases diagnosed between 2019 to 2021 centers six countries America. A templated, retrospective chart review patient characteristics at time diagnosis, including basic demographic, clinical and laboratory data, was completed. Diagnosis made radiologically or histologically for via institutional standards.Centers contributed a total 339 cases. Peru accounted 37% (n=125) patients; Brazil 16% (n=57); Chile 15% (n=51); Colombia 14% (n=48); Argentina 9% (n=29); Ecuador (n=29). The median age diagnosis 67 (IQR 59-73) 61% were male. most common risk factor nonalcoholic fatty liver disease (NAFLD, 37%), followed by hepatitis C (17%), alcohol use disorder (11%) B (12%). majority HCCs occurred setting cirrhosis (80%). HBV-related younger compared other causes, with 46 36-64).We report dramatic changes over last decade, substantial increase NAFLD-related HCC. still occurs much when causes.

Язык: Английский

---

Burden of liver disease in Brazil, 1996–2022: a retrospective descriptive study of the epidemiology and impact on public healthcare

The Lancet Regional Health - Americas, Год журнала: 2024, Номер 33, С. 100731 - 100731

Опубликована: Апрель 19, 2024

Liver disease is a major cause of mortality and morbidity worldwide its epidemiology depends on the genetic background, exposure to risk factors, access healthcare other sociodemographic characteristics. Brazil large country with diverse multicultural ethnic heritages important socioeconomic inequalities. The burden liver in Brazil, regions population unknown.

Язык: Английский

---

The burden of liver disease in Latin America

Annals of Hepatology, Год журнала: 2023, Номер 29(3), С. 101175 - 101175

Опубликована: Ноя. 3, 2023

Liver disease poses a substantial burden in Latin America. This is primarily attributed to high level of alcohol consumption and the increasing prevalence risk factors associated with metabolic dysfunction-associated steatotic liver (MASLD), such as sedentary lifestyles, easy access ultra-processed foods, obesity, type 2 diabetes mellitus. These epidemiological trends are cause for concern, especially considering that there significant challenges addressing them, due disparities screening care. In this article, we aim provide an overview current situation regarding We also discuss recent multinational proposals designed address growing MASLD via its integration into existing non-communicable diseases policies, at both local global levels. Additionally, emphasize urgent need establish effective public health policies target excessive consumption. Furthermore, development transplantation programs, areas improvement medical education research capabilities, how fostering extensive collaboration among all stakeholders crucial region.

Язык: Английский

---

Liver transplantation in Latin America: reality and challenges

The Lancet Regional Health - Americas, Год журнала: 2023, Номер 28, С. 100633 - 100633

Опубликована: Ноя. 18, 2023

Healthcare systems in Latin America are broadly heterogeneous, but all of them burdened by a dramatic rise liver disease. Some challenges that these countries face include an increase patients requiring transplant, insufficient rates organ donation, delayed referral, and inequitable or suboptimal access to transplant programs post-transplant care. This could be improved expanding the donor pool through implementation education for citizens referring physicians, as well inclusion extended criteria donors, living donors split transplantation. Addressing shortcomings will require national shifts aimed at improving infrastructure, increasing awareness training medical personnel, providing equitable care patients.

Язык: Английский

---